Aphria Inc. kondigt tweede opeenvolgende kwartaal van winstgevendheid en positief gecorrigeerde EBITDA aan – Canada NewsWi


Translating…


De Beste Kwaliteit CBD Olie?

MHBioShop CBD Olie Specialist  


Pour la meilleure qualité d’Huile de CBD Visitez

HuileCBD.be specialiste Huile de CBD


   

Net Income Increases 4.5% and Adjusted EBITDA Increases Four-fold from the Prior Quarter
Adult-Use Cannabis Revenue Increases 8% from Prior Quarter
Maintains Strong Balance Sheet and Cash Position to Support Future Growth
Reiterates Fiscal Year 2020 Outlook

LEAMINGTON, ON, Oct. 15, 2019 /CNW/ – Aphria Inc. (“Aphria” or the “Company“) (TSX: APHA and NYSE: APHA) today reported its results for the first quarter ended August 31, 2019. All amounts are expressed in thousands of Canadian dollars, unless otherwise noted and except for per gram, kilogram, kilogram equivalents, and per share amounts.

“We are pleased to report a second consecutive quarter of profitable growth with strong contribution from our Canadian cannabis operations. Our success was also driven by our international business and the strength and growth of our brands, particularly Broken Coast, despite a small fire at our British Columbia facility at the end of the quarter. This solid start to the year keeps us on track to achieve our fiscal year 2020 financial outlook,” stated Irwin D. Simon. “Going forward, we remain focused on our highest-return priorities both in Canada and internationally as our team furthers the development of our medical and adult-use cannabis brands to drive growth through innovation and return value to shareholders.”

Key Operating Highlights

  • Net revenue of $126.1 million in the first quarter, an increase of 849% from prior year quarter and decrease of 2% from prior quarter.
  • Revenue for adult-use cannabis of $20.0 million in the first quarter, an increase of 8% from prior quarter.
  • Net income of $16.4 million and adjusted EBITDA of $1.0 million in the first quarter.
  • Adjusted EBITDA from cannabis operations of $1.3 million in the first quarter.
  • Ended quarter with a strong balance sheet and liquidity, including $464.3 million of cash, cash equivalents and liquid marketable securities, to fund planned Canadian and International growth.
  • Aphria One facility in full crop rotation with more than 600,000 plants.
  • On-track for annual production capacity of 255,000 kilograms when all facilities are fully licensed and operational.
  • Launch of Plant Positivity, Aphria’s social impact platform that aims to provide greater education and access to plants within the communities the Company serves.
  • Official roofing ceremony for Aphria’s indoor facility in Neumünster, Germany.
  • Completion of Aphria’s Cannabis Vault in Bad Bramstedt, Germany.
  • Aphria’s subsidiary Marigold Project Jamaica Limited officially opened its first retail Herb House at the Peter Tosh Square, Unit #51, Pulse Center, 38a Trafalgar Road, overlooking the Peter Tosh Museum in New Kingston, Jamaica.
  • Signed on as a brand partner for the PAX Era device and platform.

Subsequent Events

  • Launch of “Aphria Educates”, a program aimed to educate Canadian adults on responsible and safe use of all cannabis products legally available now and in the future.
  • Health Canada advised the Company on October 11, 2019 that they are in the process of expediting the issuance of Aphria Diamond’s licence.

Key Financial Highlights

Three months ended

Three months ended

August 31, 2019

August 31, 2018

Net revenue

$126,112

$13,292

Gross profit

$45,421

$13,764

Adjusted cannabis gross profit 1

$15,331

$8,458

Adjusted cannabis gross margin 1

49.8%

63.6%

Adjusted distribution gross profit 1

$12,223

N/A

Adjusted distribution gross margin 1

12.8%

N/A

Net income

$16,441

$21,176

Adjusted EBITDA 1

$1,035

($3,964)

Q1-2020

Q4-2019

Distribution revenue

$95,327

$99,186

Net cannabis revenue

$30,785

$28,608

Net revenue

$126,112

$128,568

kilogram equivalents sold 1

5,969

5,574

Cash cost to produce dried cannabis / gram 1

$1.43

$1.35

“All-in” cost of goods sold / gram 1

$2.52

$2.35

Adjusted EBITDA from cannabis operations 1

$1,329

$1,851

Adjusted EBITDA from businesses under development 1

($4,234)

($5,514)

Adjusted EBITDA from distribution operations 1

$3,940

$3,872

Cash and cash equivalents & marketable securities

$464,319

$570,996

Working capital

$612,973

$642,284

Capital and intangible asset expenditures – wholly-owned subsidiaries 1

$19,277

$26,828

Capital and intangible asset expenditures – majority-owned subsidiaries1

$20,071

$16,943

Strategic investments1

$34,722

$6,862

Net revenue for the three months ended August 31, 2019 was $126.1 million, an increase of 849% from $13.3 million in the same period last year. First quarter fiscal 2020 net revenues were lower when compared to the prior quarter net revenues of $128.6 million as a result of a decrease in distribution revenue from $99.2 million to $95.3 million associated with a change in business strategy at CC Pharma to maximize profitability after recent changes in the German government’s medical reimbursement model. The decrease in distribution revenue was partially offset by an increase in net cannabis revenue of $30.8 million from $28.6 million. Net revenue includes over 3,317 kilogram equivalents sold for the adult-use market and 1,354 kilogram equivalents for medical cannabis sales. The Company estimates the impact on revenue from the small fire at Broken Coast to be approximately $1.5 million in the quarter; however, the majority of the lost quarterly revenue will be reported in the Company’s second quarter.

The average retail selling price of medical cannabis (exclusive of wholesale), before excise tax, decreased to $7.56 per gram in the quarter, compared to $7.66 in the prior quarter, primarily related to a higher percentage of total medical sales coming from Aphria. The average selling price of adult-use cannabis, before excise tax, increased to $6.02 per gram in the quarter, compared to $5.73 per gram in the prior quarter.

Adjusted cannabis gross profit for the first quarter was $15.3 million, with an adjusted cannabis gross margin of 49.8%, compared to $15.2 million with an adjusted gross margin of 53.0% in the prior quarter. The decrease in adjusted gross margin was primarily due to lower sales of higher margin items due to the Broken Coast fire and temporary higher costs per gram.

Adjusted distribution gross profit for the first quarter was $12.2 million, with an adjusted gross margin of 12.8%, compared to $12.3 million with an adjusted gross margin of 12.4% in the prior quarter.

Selling, general, and administrative costs in the quarter decreased to $41.4 million from $60.0 million in the prior quarter, and increased from $24.1 million in the prior year. The decrease from the prior quarter is mainly related to the decrease of $19.5 million in transaction costs primarily associated with the issuance of the senior convertible debenture and $3.9 million general and administrative costs, partially offset by $1.9 million in share-based compensation and $0.5 million in amortization.

Net income for the first quarter of fiscal 2020 was $16.4 million or $0.07 per share, compared to net income of $15.8 million or $0.05 per share in the prior quarter, and net income of $21.2 million or $0.09 per share for the same period last year. The increase in net income was primarily due to the increase in gross profit and the net fair value adjustment for biological assets, and decrease in the SG&A related to G&A and non-operating income.

Adjusted EBITDA increased $0.8 million to $1.0 million for the first quarter compared to $0.2 million in the prior quarter. Adjusted EBITDA from cannabis operations for the first quarter was $1.3 million compared to $1.8 million in the prior quarter. The adjusted EBITDA loss from businesses under development for the first quarter was $4.2 million compared to a loss of $5.5 million in the prior quarter. Adjusted EBITDA from distribution operations for the first quarter was $3.9 million, flat compared to the prior quarter. The increased adjusted EBITDA is primarily attributable to cost containment strategies employed across the businesses under development.

1 – In this press release, reference is made to adjusted cannabis gross profit, adjusted cannabis gross margin, adjusted distribution gross profit, adjusted distribution gross margin, adjusted net loss, adjusted EBITDA from cannabis operations, adjusted EBITDA from businesses under development, adjusted EBITDA from distribution operations, kilogram equivalents sold, cash costs to produce dried cannabis per gram, “all-in” costs to produce dried cannabis per gram and investments in capital and intangible assets – wholly-owned subsidiaries, which are not measures of financial performance under International Financial Reporting Standards (IFRS). These metrics and measures are not recognized measures under IFRS do not have meanings prescribed under IFRS and are as a result unlikely to be comparable to similar measures presented by other companies. These measures are provided as information complimentary to those IFRS measures by providing a further understanding of our operating results from the perspective of management. As such, these measures should not be considered in isolation or in lieu of review of our financial information reported under IFRS. Definitions and reconciliations for all terms above can be found in the Company’s August 31, 2019 Management’s Discussion and Analysis, filed on SEDAR and EDGAR.

Outlook

For fiscal year 2020, the Company is reaffirming its guidance of:

  • Net revenue of approximately $650 million to $700 million, with distribution revenue representing slightly more than half of the total net revenue
  • Adjusted EBITDA of approximately $88 million to $95 million

Conference Call

Aphria executives will host a conference call to discuss these results today at 9:00 am ET. To listen to the live call, dial (888) 231-8191 from Canada and the U.S. or (647) 427-7450 from International locations and use the passcode 6099303. A telephone replay will be available approximately two hours after the call concludes through October 29, 2019. To access the recording dial (855) 859-2056 and use the passcode 6099303.

There will also be a simultaneous, live webcast available on the Investors section of Aphria’s website at aphriainc.com. The webcast will be archived for 30 days.

We Have A Good Thing Growing

About Aphria

Aphria Inc. is a leading global cannabis company driven by an unrelenting commitment to our people, the planet, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria Inc. has been setting the standard for the low-cost production of high-quality cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria Inc. is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria Inc. drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents.

For more information, visit: aphriainc.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws and are expressly qualified by this cautionary statement. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to Net revenue and Adjusted EBITDA guidance. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the cannabis industry in Canada generally, income tax and regulatory matters, including delays in the issuance of licenses; the ability of Aphria to meet its liquidity requirements to fund ongoing operations; the ability of Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations.

Readers are cautioned that the foregoing list is not exhaustive and should consider as other factors discussed under the heading “Risk Factors” in Aphria’s most recent Annual Information Form and Management’s Discussion and Analysis for the financial year ended May 31, 2019 and under the heading “Industry Trends and Risks” in Aphria’s Management’s Discussion and Analysis for the three months ended August 31, 2019, each available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws. Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Below schedule is an excerpt of Aphria Inc.’s financial statements prepared on a basis consistent with IFRS for the three months ended on August 31, 2019 and filed on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. This schedule does not contain all the information in Aphria Inc.’s financial statements that is important to you. You should read the financial statements and Management’s Discussion and Analysis carefully to obtain a comprehensive understanding of Aphria Inc.’s financial statements under IFRS and related information.

      

      

      Tr>

      

      

      

      Tr>

      

      

      

      Tr>

      

      

      Tr>

      

      

      

     

      

      

      Tr>

      

      

      

     

      

      

      Tr>

      

      

      

      Tr>

      

      

      

      Tr>

      

      Tr>

      

      

     

      

      

      Tr>

      

      

      

     

      

      

      

      Tr> tbody> table> div>   Div> Div>

 
  
   

     

      

      

      

     

      

      

      

      

      Tr>

      

      

      

      Tr>

      

      

      Tr>

      

      

      

      Tr>

      

      

      

      Tr>

      

      

      

      Tr>

      

      

      

      Tr>

      

      

      

      Tr>

      

      Tr>

      

      

      

      Tr>

      

      

      

      Tr>

      

      

      

      Tr>

      

      

      

      Tr>

      

      

      

      Tr>

      

      

      

      Tr>

      

     

      

      

      

      

      Tr>

      

      

      Tr>

      

      

      Tr>

      

      

      

      Tr>

      

      

      

      Tr>

      

     

      

      

      

      

      Tr>

      

      

      

      Tr>

      

      

      

      Tr>

      

      

      

      Tr>

      

     

      

      

      

      

      Tr>

      

      

      

      Tr>

      

      

      Tr>

      

      

      Tr>

      

      

      

      Tr>

      

      

      Tr>

      

      Tr>

      

      Tr> tbody> table> div>   Div> Div>

 
  
   

Aphria Inc.
Consolidated Statements of Income and Comprehensive Income

(In thousands of Canadian dollars, except share and per share amounts)

For the three months ended
August 31,

Note

2019

2018

Revenue from cannabis products

$ 35,079

$ 13,292

Distribution revenue

95,327

Excise taxes

(4,294)

Net revenue

126,112

13,292

Production costs

6

15,454

4,834

Cost of goods purchased

83,104

Gross profit before fair value adjustments

27,554

8,458

Fair value adjustment on sale of inventory

6

7,286

4,205

Fair value adjustment on growth of biological assets

7

(25,153)

(9,511)

Gross profit

45,421

13,764

Operating expenses:

General and administrative

24

22,305

8,851

Share-based compensation

25

4,956

6,122

Selling, marketing and promotion

7,814

4,741

Amortization

5,008

3,274

Research and development

610

262

Transaction costs

735

865

41,428

24,115

Td>        br> td>        br> td>        br> td>      

Bedrijfsopbrengsten

br> td>        br> td>        br> td>       

3.993

(10,351)

br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>       Tr>
br> td>       

Financiële opbrengsten (kosten), netto

br> td>        br> td>       

26

(5,257)

1.059

br> td>       

Niet-operationele inkomsten

br> td>        br> td>       

27

20,303

34.430

br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>      

Inkomsten voor inkomstenbelastingen

br> td>        br> td>        br> td>       

19.039

25,138

br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>      

Inkomstenbelastingen

br> td>        br> td>       

16

2.598

3,962

Netto-inkomen

br> td>        br> td>        br> td>       

16.441

21,176

br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>      

Niet-gerealiseerde resultaten

br> td>        br> td>        br> td>        br> td>        br> td>       Tr>
br> td>       

Overig totaalresultaat

br> td>        br> td>        br> td>       

(1.686)

Totaal inkomen

br> td>        br> td>        br> td>       

$ 14.755

$ 21,176

br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>      

Het totaalresultaat (verlies) kan worden toegeschreven aan:

br> td>        br> td>        br> td>        br> td>       Tr>
br> td>       

Aandeelhouders van Aphria Inc.

br> td>        br> td>        br> td>       

14.926

21.387

br> td>       

Minderheidsbelang

br> td>        br> td>       

23

(171)

(211)

br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>       

$ 14.755

$ 21,176

br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>      

Gewogen gemiddeld aantal gewone aandelen – basis

br> td>        br> td>        br> td>       

251,163,059

225.659.684

Gewogen gemiddeld aantal gewone aandelen – verwaterd

br> td>        br> td>        br> td>       

252.741.610

230,366,310

br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>        br> td>      

Winst per aandeel – basis

br> td>        br> td>       

29

$ 0,07

$ 0.09

Winst per aandeel – verwaterd

br> td>        br> td>       

29

$ 0,07

$ 0.09

Aphria Inc.
Geconsolideerde jaarrekening Financiële positie

br> (In duizenden Canadese dollars)

Opmerking

31 augustus, 2019

31 mei,
2019

Activa

br> td>        br> td>        br> td>      

Vlottende activa

br> td>        br> td>        br> td>       Tr>
br> td>       

Geldmiddelen en kasequivalenten

br> td>       

$ 449,205

$ 550.797

br> td>       

Verhandelbare effecten

4

15,114

20,199

br> td>       

Debiteuren

br> td>       

47,264

25.488

br> td>       

Prepaids en andere vlottende activa

5

18.936

23,391

br> td>       

Voorraad

6

112.980

91,529

br> td>       

Biologische activa

7

29.887

18.725

br> td>       

Ontvangende promessen

15

39.20000/b>

39.20000/span>

br> td>       

Huidig ​​gedeelte van te ontvangen converteerbare obligaties

12

23,355

11.500

br> td>        br> td>        br> td>        br> td>        br> td>       

735.941

780.829

br> td>       

Kapitaalgoederen

9

542.20000/b>

503.898

br> td>       

Immateriële activa

10

388.367

392.056

br> td>       

Te ontvangen converteerbare obligaties

12

10.030

20.730

br> td>       

Interesse in aandelenbelangen

13

9.311

br> td>       

Langetermijninvesteringen

14

87.413

64.922

br> td>       

Goodwill

11

669.618

669.846

br> td>        br> td>        br> td>        br> td>        br> td>       

$ 2.433.569

$ 2.441.592

Verplichtingen

br> td>        br> td>        br> td>      

Kortlopende verplichtingen

br> td>        br> td>        br> td>       Tr>
br> td>       

Crediteuren en overlopende passiva

br> td>       

$ 90.773

$ 105.813

br> td>       

Te betalen inkomstenbelasting

br> td>       

2.148

2.722

br> td>       

Uitgestelde inkomsten

br> td>       

22.687

23,678

br> td>       

Lopend gedeelte van leaseverplichtingen

3

1.080

br> td>       

Huidig ​​deel van de langlopende schulden

18

6,280

6,332

br> td>        br> td>        br> td>        br> td>        br> td>       

122.968

138.545

Langlopende schulden

br> td>        br> td>        br> td>       Tr>
br> td>       

Leaseverplichtingen

3

5.284

br> td>       

Langlopende schulden

18

54,204

60.895

br> td>       

Converteerbare obligaties

19

407,159

421,366

br> td>       

Uitgestelde belastingverplichting

16

88.632

87.633

br> td>        br> td>        br> td>        br> td>        br> td>       

678.247

708,439

Eigen vermogen

br> td>        br> td>        br> td>       Tr>
br> td>       

Aandelenkapitaal

20

1.661.641

1.655.273

br> td>       

Warrants

21

1.336

1,336

br> td>       

Op aandelen gebaseerde betalingsreserve

br> td>       

37,197

36,151

br> td>       

Cumulatief ander omvangrijk verlies

br> td>       

(1.805)

(119)

br> td>       

Minderheidsbelang

23

28,238

28,409

br> td>       

Ingehouden inkomsten

br> td>       

28.715

12,103

br> td>        br> td>        br> td>        br> td>        br> td>       

1.755.322

1.733,153

br> td>        br> td>        br> td>        br> td>        br> td>       

$ 2.433.569

$ 2.441.592

      

      

      Tr>

      

      Tr>

      

      

      Tr>

      

      

      Tr>

      

      

      Tr>

      

      

      Tr>

      

      

      Tr>

      

      

      Tr>

      

      

      Tr>

      

      

      Tr>

      

      

      Tr>

      

      

      Tr>

      

      

     

      

      

      Tr> tbody> table> div>   Div> Div>

 
  
   

Voor de drie maanden eindigend
31 augustus,

br> td>        br> td>       

2019

2018

br> td>       

Netto-inkomen (verlies)

br> td>        br> td>       

$ 16.441

$ 21,176

br> td>       

Inkomstenbelastingen (herstel)

br> td>        br> td>       

2.598

3,962

br> td>       

Financieringskosten (inkomsten), netto

br> td>        br> td>       

5.257

(1.059)

br> td>       

Niet-operationeel (inkomsten) verlies

br> td>        br> td>       

(20,303)

(34.430)

br> td>       

Amortization

br> td>        br> td>       

9.218

4,706

br> td>       

Op aandelen gebaseerde beloning

br> td>        br> td>       

4.956

6,122

br> td>       

Reële waarde aanpassing bij verkoop van voorraden

br> td>        br> td>       

7.286

4,205

br> td>       

Aanpassing van de reële waarde bij groei van biologische activa

br> td>       

(25,153)

(9.511)

br> td>       

Transactiekosten

br> td>        br> td>       

735

865

br> td>       

Aangepaste EBITDA van bedrijven in ontwikkeling

br> td>       

4.234

3.565

br> td>       

Aangepaste EBITDA van distributie-operaties

br> td>        br> td>       

(3.940)

Aangepaste EBITDA van cannabisactiviteiten

br> td>       

$ 1.329

$ (399)

      

      

      Tr>

      

      Tr>

      

      

      Tr>

      

      

      Tr>

      

      

     

      

      

      Tr> tbody> table> div>   Div> Div>

BRON Aphria Inc.

Neem voor meer informatie contact op met Tam: neem contact op met Tam: Macgregor, vice-president, Communicatie & Public Affairs, Aphria Inc., tamara.macgregor@aphria.com, 437-343-4000; Voor vragen van beleggers kunt u contact opnemen met: Katie M. Turner, ICR, Inc., katie.turner@icrinc.com, 646-277-1228

Gerelateerde links

http://aphria.com/
p>            Div>          Div>             Section>    Article>
Lees Meer

Voor de drie maanden eindigend
31 augustus,

br> td>        br> td>       

2019

2018

br> td>       

Aangepaste EBITDA van cannabisactiviteiten

br> td>        br> td>       

$ 1.329

$ (399)

br> td>       

Aangepaste EBITDA van bedrijven in ontwikkeling

br> td>       

(4.234)

(3.565)

br> td>       

Aangepaste EBITDA van distributie-operaties

br> td>        br> td>       

3.940

Aangepaste EBITDA

br> td>        br> td>       

$ 1.035

$ (3.964)

Leave a Comment